To evaluate health-related quality of life following robotic and open radical cystectomy as a treatment for bladder cancer.
Using the Randomized Open versus Robotic Cystectomy (RAZOR) trial population we assessed health-related quality of life by using the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index and the Short Form 8 Health Survey at baseline, 3- and 6-months postoperatively.